PTAB Upholds Validity of BMS Patent

The PTAB issued a Final Written Decision upholding the validity of Bristol-Myers Squibb’s U.S. Patent 8,476,239, which had been challenged by Momenta in IPR2015-01537.  According to documents filed with the PTAB during the IPR, the ‘239 patent covers stable formulations of a protein called “CTLA4Ig.”  This protein is sold by BMS under the  tradename Orencia® (abatacept), which is approved to treat rheumatoid arthritis.

Selected documents related to this and other IPRs concerning biologic patents can be found on our IPR tracker page.

Download PDF